Healthcare Technology Report March 25, 2024
Dexcom has received clearance from the U.S. Food and Drug Administration for its new over-the-counter continuous glucose monitor (CGM) named Stelo. Unveiled on March 5, 2024, Stelo is designed for Type 2 diabetes patients who do not use insulin, making it the first glucose biosensor of its kind that does not require a prescription. The device, set to be available for online purchase this summer, offers real-time glucose level tracking through small sensors worn on the upper arm. Unlike Dexcom’s existing G7 CGM system, which requires a prescription, Stelo aims to provide a simpler experience with a unique platform tailored specifically to the needs of...
Today's Sponsors
Today's Sponsor